Accreditation

Academy of Next Wave Investigators™ in CLL and NHL

Date and Location – April 28-29, 2023; Scottsdale, Arizona
Jointly provided by Partners for Advancing Clinical Education (PACE) and Bio Ascend, LLC

Target Audience

This activity is intended for physicians who care for patients with CLL and NHL.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate techniques to develop the skills of young investigators in CLL and NHL, including presentation, leadership, and career development skills
  • Facilitate the presentation of clinical data from young investigators and allow feedback from dedicated mentors on how best to focus data presentation

  • Foster mentor-mentee relationships among senior and junior physicians caring for patients with CLL and NHL

  • Assess strategies for young investigators to participate in clinical trials, including the importance of clinical trial design, trial endpoints, and protocol adherence

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Faculty

Conflicts of Interest

John P. Leonard, MD – Co-Chair
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chairman, Department of Medicine
Weill Cornell Medicine
New York, New York

Advisor, Consultant, Speaker: AbbVie, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Calithera, Caribou Biosciences, Constellation, Eisai, Epizyme, Genmab, Grail, Incyte, Janssen, Lilly, MEI Pharma, Merck, Mustang Bio, Novartis, Pfizer, Roche/Genentech, Seagen, Second Genome, Sutro

Matthew S. Davids, MD, MMSc – Co-Chair
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisor, Consultant, Speaker: AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Lilly, Genentech, Genmab, Janssen, Merck, MingSight, Ono Pharmaceuticals, Secura Bio, Syros Pharmaceuticals, Takeda, TG Therapeutics
Educational Programs: Aptitude Health, AXIS Medical Education, Bio Ascend, Curio Science, Medscape Education, PeerView Institute for Medical Education, Physcians’ Education Resource, PlatformQ Health Education, Plexus Communications, Research to Practice
Researcher: AbbVie, Ascentage Pharma, AstraZeneca, Genentech, Novartis, Secura Bio, TG Therapeutics
Royalties : Up-to-Date

Jonathon Cohen, MD, MS
Associate Professor
Department of Hematology and Medical Oncology
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Atlanta, Georgia

Advisor, Consultant, Speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, HutchMed, Janssen, Lilly/Loxo
Researcher: AstraZeneca, BioInvent, BMS/Celgene, Genentech, HutchMed, Lilly/Loxo, Novartis, Takeda

Nicole Lamanna, MD
Associate Professor of Medicine
Hematology / Oncology Division
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York

Advisor, Consultant, Speaker: AbbVie, AstraZeneca, BeiGene, Lilly/Loxo, Janssen, Pharmacyclics
Researcher: AbbVie, AstraZeneca, BeiGene, Lilly/Loxo, MingSight, Octapharma, Oncternal, TG Therapeutics

Javier Munoz, MD, MS, MBA, FACP
Director, Lymphoma Program
Mayo Clinic
Phoenix, Arizona

Advisor, Consultant, Speaker: AbbVie/Pharmacyclics, Acrotech/Aurobindo, ADC Therapeutics, Alexion, AstraZeneca, Bayer, BeiGene, BMS, Curio, Debiopharm, Epizyme, Fosunkite, Genentech/Roche, Genmab, Gilead/Kite Pharma, Innovent, Janssen, Juno/Celgene, Karyopharm, Kyowa Kirin, Lilly/Loxo, MEI Pharma, MorphoSys/Incyte, Novartis, OncView, Pfizer, Physicians’ Education Resource, Seattle Genetics, Servier, Targeted Oncology, TG Therapeutics, Verastem, Zodiac
Researcher: Bayer, Celgene, Genentech, Gilead/Kite Pharma, Incyte, Janssen, Merck, Millennium, Pharmacyclics, Portola, Seattle Genetics

Loretta Nastoupil, MD
Associate Professor and Deputy Chair
Section Chief, New Drug Development
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisor: AbbVie, Genmab, Regeneron
Consultant: AbbVie, Genmab, Regeneron
Researcher: BMS, Caribou Biosciences, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
Speaker: AbbVie, Genmab, Regeneron

Sameer Parikh, MBBS
Consultant and Assistant Professor of Medicine and Oncology
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Consulting Fees to Institution: AbbVie, Amgen, AstraZeneca, Genentech, Janssen, Kite Pharma, Merck, MingSight Pharmaceuticals, Novalgen Limited, Pharmacyclics, TG Therapeutics
Research Funding to Institution: AstraZeneca, Genentech, Janssen, Merck

Jennifer Woyach, MD
Professor
Division of Hematology
The Ohio State University Comprehensive Cancer Center – James
Columbus, Ohio

Advisor: AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, Loxo, Newave, Pharmacyclics
Consultant: AbbVie, Arqule, AstraZeneca, BeiGene, Genentech, Janssen, Loxo, Newave, Pharmacyclics
Researcher: Karyopharm, MingSight, Pharmaceuticals MorphoSys, Schrodinger, Verastem
Speaker: AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, Loxo, Newave, Pharmacyclics
The young investigators reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Investigator
Conflicts of Interest
Aseel Alsouqu, MD

Has no relevant financial relationship(s) to disclose with ineligible companies

Emily C. Ayers, MD, MSCE

Consultant / Advisor / Speaker: Genentech, ADC Therapeutics

Titas Banerjee, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Ayushi Chauhan, MBBS
Has no relevant financial relationship(s) to disclose with ineligible companies
Hua-Jay Jeffrey Cherng, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Dai Chihara, MD, PhD
Has no relevant financial relationship(s) to disclose with ineligible companies
Caitlin Gribbin, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Ashwath Gurumurthi, MD

Consultant / Advisor / Speaker: Kite Pharma

Paul J. Hampel, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Swetha Kambhampati, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Yasmin Karimi, MD
Advisory Board: ADC Therapeutics
Mwanasha Merrill, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Patrizia Mondello, MD, MSc, PhD
Has no relevant financial relationship(s) to disclose with ineligible companies
Christine E. Ryan, MD
Speaker: Curio Science
Yun K. Ryu, MD, PhD
Has no relevant financial relationship(s) to disclose with ineligible companies
Paolo Strati, MD

Consultant / Advisor / Speaker: Kite, Gilead, Roche, Genentech, AstraZeneca, Acerta, Sobi, Incyte, Morphosis, Hutchinson, MediPharma, TG Therapeutics, ADC Therapeutics; Researcher: AstraZeneca, ALX Oncology, ADC Therapeutics

Seda Tolu, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Mazie Tsang, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
Yumeng Zhang, MD
Has no relevant financial relationship(s) to disclose with ineligible companies
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Bio Ascend planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit

To receive CE credit, learners must follow these steps:
  1. Visit https://www.paceducation.com/nextwave23
  2. Complete the activity evaluation
  3. Upon completion of all evaluation questions your credit will be made available for download immediately.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact bunyasaranand@bioascend.com prior to the live event.

Fee Information

There is no fee for this educational activity.

Joint Accreditation Statement

UNMC Joint Accreditation Logo December 2020

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bio Ascend, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.